On November 21, the 5th China Health Industry Development & Rehabilitation Services Conference was held in Beijing. The United Laboratories International Holdings Limited (3933.HK) was recognized for its outstanding performance in sustainable development system building, social responsibility fulfillment, and corporate governance, and was successfully selected as a “2025 China ESG Dandelion Model Case,” becoming an exemplary company within the industry.

About the “China ESG Dandelion Model Case”

The “China ESG Dandelion Model Case” was launched by China Times under the framework of the China Health Industry Development Conference. It aims to identify and recognize listed companies that have made outstanding contributions in the areas of environment (E), social (S), and governance (G) and serve as leading examples in the capital market. The selection focuses on the latest industry trends, emphasizes long-term value creation and sustainable development capabilities, and is regarded as one of the most influential ESG case review initiatives in China’s health industry.

The case selection adheres to the principles of openness, fairness, and professionalism. The editorial team of China Times conducts targeted solicitation, combining self-nomination by companies with recommendations from industry experts, and follows a rigorous three-round review process: broad collection → expert pre-screening → authoritative final review. This ensures that the selected companies demonstrate industry representativeness, credibility, and forward-looking vision. The initiative aims to promote positive industry influence, advance healthy development in the medical and health sector, and establish a benchmark of “Oscar-level” recognition in the field of human health.

Looking ahead, TUL will continue to deeply integrate ESG principles into corporate strategy and daily operations, enhance environmental management effectiveness, and strengthen its governance framework. The Company will uphold higher standards to drive green development and fulfill its social responsibilities, actively giving back to society through concrete actions and contributing further to the sustainable development of the pharmaceutical industry.